NCT00943735View on ClinicalTrials.gov

"This Is An Open-Label Study To Evaluate Fesoterodine Plus Your Way Patient Support Plan In Patients With Symptoms Of Overactive Bladder"

CompletedOBSERVATIONAL

Enrollment

774

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions

Overactive Bladder

Interventions

DRUG

Fesoterodine

Fesoterodine 4 mg and 8 mg QD

BEHAVIORAL

Your Way

early intervention after treatment initiation and before patients have an opportunity to discontinue medication; reinforcing the treatable nature of OAB